- ISIN
- US62855J1043
- CUSIP
- 62855J104
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- IPO Date
- Oct 5, 1995
Highlights
- Market Cap
- $270.12M
- Enterprise Value
- $372.72M
- EPS (TTM)
- -$1.20
- Total Revenue (TTM)
- $806.60M
- Gross Profit (TTM)
- $555.20M
- EBITDA (TTM)
- -$58.10M
- Year Range
- $2.81 - $8.59
- Target Price
- $6.00
- ROA (TTM)
- -17.62%
- ROE (TTM)
- -37.05%
- Avg. Volume (1M)
- 2M
- Avg. Volume Value (1M)
- $7.73M
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
MYGN Performance Chart
Myriad Genetics, Inc. (MYGN) is down 53.5% since the beginning of the year. At $3 per share, MYGN is trading 66.7% below its 52-week high of $9. Investors who bought $1,000 worth of MYGN shares 5 years ago would now be looking at an investment worth $90.
Loading charts...
Compare this symbol against anything
Returns By Period
Myriad Genetics, Inc. (MYGN) has returned -53.50% so far this year and -26.85% over the past 12 months. Over the last ten years, MYGN has returned -21.16% per year, falling short of the S&P 500 Index benchmark, which averaged 13.26% annually.
Myriad Genetics, Inc.
- 1D
- -46.74%
- 1M
- -52.25%
- 6M
- -49.11%
- YTD
- -53.50%
- 1Y
- -26.85%
- 3Y*
- -49.16%
- 5Y*
- -38.16%
- 10Y*
- -21.16%
- ALL TIME*
- -1.56%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
MYGN Monthly Returns History
Based on dividend-adjusted daily data since Oct 6, 1995, MYGN's average daily return is +0.08%, while the average monthly return is +1.56%. At this rate, an investment would double in approximately 3.7 years.
Historically, 49% of months were positive and 51% were negative. The best month was Feb 2000 with a return of +139.5%, while the worst month was Mar 2000 at -61.0%. The longest winning streak lasted 8 consecutive months, and the longest losing streak was 9 months.
On a daily basis, MYGN closed higher 49% of trading days. The best single day was Aug 1, 2019 with a return of +54.5%, while the worst single day was Jul 31, 2026 at -46.7%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -8.62% | -17.97% | -2.39% | 5.56% | -16.42% | 43.83% | -49.91% | -53.50% | |||||
| 2025 | -7.59% | -15.31% | -17.33% | -16.46% | -43.45% | 26.73% | -27.68% | 65.89% | 13.50% | 11.20% | -5.10% | -19.40% | -55.14% |
| 2024 | 11.76% | -2.15% | 1.86% | -8.21% | 16.30% | 7.47% | 14.35% | 1.29% | -3.32% | -19.82% | -25.91% | -15.73% | -28.37% |
| 2023 | 35.91% | -4.06% | 22.78% | -8.35% | 3.62% | 5.08% | -3.58% | -20.13% | -10.14% | -2.87% | 22.53% | 0.26% | 31.91% |
| 2022 | -4.75% | -7.27% | 3.36% | -18.65% | -6.15% | -5.56% | 45.18% | -15.31% | -14.59% | 8.70% | -2.31% | -28.38% | -47.43% |
| 2021 | 39.32% | 10.67% | -0.13% | -0.76% | -5.20% | 6.74% | 3.43% | 13.12% | -9.75% | -4.71% | -15.96% | 6.73% | 39.57% |
Benchmark Metrics
Myriad Genetics, Inc. has an annualized alpha of 8.68%, beta of 1.13, and R2 of 0.11 versus S&P 500 Index. Calculated based on daily prices since October 06, 1995.
- This stock participated in 135.59% of S&P 500 Index downside but only 93.36% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.11 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 8.68%
- Beta
- 1.13
- R²
- 0.11
- Upside Capture
- 93.36%
- Downside Capture
- 135.59%
Return for Risk
Risk / Return Rank
MYGN ranks 34 for risk / return — above 34% of stocks peers on PortfoliosLab. Its historical combined result is below the peer median.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Myriad Genetics, Inc. (MYGN) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| MYGN | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.70 | ||
| Sortino ratioReturn per unit of downside risk | -1.74 | ||
| Omega ratioGain probability vs. loss probability | 1.04 | 1.25 | -0.22 |
| Calmar ratioReturn relative to maximum drawdown | -0.39 | 2.00 | -2.40 |
| Martin ratioReturn relative to average drawdown | -0.82 | 8.49 | -9.31 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Myriad Genetics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Myriad Genetics, Inc. was 95.33%, occurring on Jul 31, 2026. The portfolio has not yet recovered.
The current Myriad Genetics, Inc. drawdown is 95.33%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-95.33%Jul 2026 | 25y 9mo | — | 25y 9moNov 2000 - now | — |
-83.47%Aug 1998 | 1y 6mo | 1y 3mo | 2y 10moFeb 1997 - Dec 1999 | — |
-81.95%Apr 2000 | 1mo 8d | 6mo 6d | 7mo 14dMar 2000 - Oct 2000 | Dot-com crash2000–2002 |
-54.00%Jul 1996 | 8mo 6d | 6mo 19d | 1y 2moNov 1995 - Jan 1997 | — |
-17.81%Feb 2000 | 4d | 13d | 17dFeb 2000 - Mar 2000 | — |
Drawdown Indicators
| MYGN | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -95.33% | -56.78% | -38.55% |
Max Drawdown (1Y)Largest decline over 1 year | -65.04% | -9.10% | -55.94% |
Max Drawdown (3Y)Largest decline over 3 years | -90.00% | -18.90% | -71.10% |
Max Drawdown (5Y)Largest decline over 5 years | -92.20% | -25.43% | -66.77% |
Max Drawdown (10Y)Largest decline over 10 years | -94.32% | -33.92% | -60.40% |
Current DrawdownCurrent decline from peak | -95.33% | -1.58% | -93.75% |
Average DrawdownAverage peak-to-trough decline | -61.37% | -10.70% | -50.67% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 31.18% | 2.14% | +29.04% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Myriad Genetics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Myriad Genetics, Inc. is priced in the market compared to other companies in the Diagnostics & Research industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for MYGN relative to other companies in the Diagnostics & Research industry. Currently, MYGN has a P/S ratio of 0.3. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for MYGN in comparison with other companies in the Diagnostics & Research industry. Currently, MYGN has a P/B value of 0.9. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with MYGN
Add Myriad Genetics, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with MYGN